Baseline characteristics and the duration of transition period of Secukinumab treatment in moderate to severe Psoriasis.
Phase of Trial: Phase IV
Latest Information Update: 13 Sep 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms PROSPECT
- 13 Sep 2018 Results presented in a Novartis media release.
- 13 Sep 2018 According to a Novartis media release, from the study has been presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.
- 08 Jun 2017 New trial record